The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.
first published: Jan 25, 2013 07:59 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty slips below 25,200, LG Electronics shares down after blockbuster debut | Closing Bell
Why markets haven’t delivered and why they will turn now
Nifty Upmove Hinges On Quarterly Earnings; Will LG Electronics See A Listing Pop?|Opening Bell Live
Live: Nifty snaps 2-day winning streak but rebounds from day's low | Closing Bell | 4K
